Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-label, First-in-human, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Actinium-225-macropa-pelgifatamab (BAY 3546828) in Participants With Advanced Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT06052306 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT06052306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06052306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-label, First-in-human, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Actinium-225-macropa-pelgifatamab (BAY 3546828) in Participants With Advanced Metastatic Castration Resistant Prostate Cancer (mCRPC)
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 20, 2023
Completion date
August 10, 2031
Enrollment
232 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer